Migrants arriving from high tuberculosis (TB)-incidence countries may pose a significant challenge to TB control programmes in the host country. TB surveillance data for 2007–2013 submitted to the European Surveillance System were analysed. Notified TB cases were stratified by origin and reporting country. The contribution of migrant TB cases to the TB epidemiology in EU/EEA countries was analysed. Migrant TB cases accounted for 17.4% (n = 92,039) of all TB cases reported in the EU/EEA in 2007–2013, continuously increasing from 13.6% in 2007 to 21.8% in 2013. Of 91,925 migrant cases with known country of origin, 29.3% were from the Eastern Mediterranean, 23.0% from south-east Asia, 21.4% from Africa, 13.4% from the World Health Organization European Region (excluding EU/EEA), and 12.9% from other regions. Of 46,499 migrant cases with known drug-susceptibility test results, 2.9% had multidrug-resistant TB, mainly (51.7%) originating from the European Region. The increasing contribution of TB in migrants from outside the EU/EEA to the TB burden in the EU/EEA is mainly due to a decrease in native TB cases. Especially in countries with a high proportion of TB cases in non-EU/EEA migrants, targeted prevention and control initiatives may be needed to progress towards TB elimination.

Introduction
The tuberculosis (TB) notification rate in the European Union and European Economic Area (EU/EEA) declined from 16.8 per 100,000 population in 2007 to 12.7 per 100,000 in 2013 [1]. However, in some low-incidence countries, the decline in TB notification rate has slowed down, especially in countries reporting a high proportion of TB cases in individuals of foreign origin, i.e. migrants. In general, migration is influenced by socioeconomic and political factors [2]. Economic, social and political stability is relatively high in the EU/EEA which thus attracts immigrants from many low-income countries around the world [3]. On average (years 2007–2012), 1.5 million migrants from outside the EU/EEA were registered annually in EU and EEA countries [4]. A considerable proportion of these migrants are coming from countries with a high TB burden such as Bangladesh, Brazil, China, India, Morocco, Pakistan, Russian Federation, Somalia and Ukraine [5]. They may arrive in the EU/EEA with active TB disease, or with latent TB infection (LTBI). To detect TB disease in migrants, several EU/EEA countries have introduced (pre-)entry screening programmes [6-8]. Screening of migrants for LTBI is also being explored by some countries, such as the Netherlands [9]. However, screening programmes will not identify all TB or LTBI cases among migrants, due to the limited sensitivity of the current screening tests (mainly chest x-ray and tuberculin skin test or interferon gamma release assay). Also, not all migrant groups are covered by the screening programme, e.g. undocumented migrants are often not included. In addition, migrants frequently travel back to their country of origin where they may be (re-)infected with TB [10].

Migrants developing TB may pose a challenge to TB programmes in the EU/EEA due to language and cultural differences [11]. Also, undocumented migrants may not access the healthcare system due to fear of deportation, and migrants whose stay is legal may be unfamiliar with the healthcare system and therefore encounter problems in seeking healthcare [12]. Since countries with low TB notification rates report high numbers of TB cases in migrants in particular, it is important to study this phenomenon because addressing TB in migrants will be essential to achieving the goal of TB programmes, i.e. TB elimination [13]. Therefore, the aim of this study is to quantify and to geographically...
and epidemiologically characterise migration-related importation of TB to EU/EEA countries.

Methods

The European Centre for Disease Prevention and Control (ECDC) has collected case-based TB surveillance data from EU and EEA countries since 2007 and stored them in a common database (The European Surveillance System, TESSy) hosted by ECDC. Designated national surveillance institutions are responsible for data reporting to TESSy and for data validation.

The detailed data collection methods and definitions are described elsewhere [1]. TB cases were defined according to agreed case definitions published by the European Commission [14] and confirmed, probable and possible cases were included in the analysis. Surveillance data reported by 29 EU/EEA countries and covering the period from 2007 to 2013 were extracted from the database on 3 October 2014. Place of birth was used as a proxy indicator for the geographic origin of a TB case in most countries; except for Austria, Belgium, Greece, Poland, Hungary (from 2010 onwards) and for Malta (only in 2010) where citizenship was used. Place of birth outside EU/EEA borders was used as proxy for migrant TB in most countries. Non-EU/EEA citizenship was used for Austria, Belgium, Greece, Poland, Hungary (from 2010 onwards) and for Malta (only in 2010).

The analysis was restricted to TB cases with known origin. The areas of origin were defined according to the World Health Organization (WHO) regions described in the Global Tuberculosis Report, 2013 [15].

The European Region refers to the WHO European Region excluding the EU and EEA (Iceland, Liechtenstein and Norway) countries. To assign country of origin (based on place of birth), we used the ISO 3166–1 codes for countries, dependent territories, and special areas of geographical interest which are published by the International Organization for Standardization [16]. The origin of cases reported by or from populated Overseas Countries and Territories of EU countries was assigned according to their geographic location and such cases counted as cases in individuals of non-EU/EEA origin. Cases reported/coded in the system as originating (based on place of birth) either from ‘Soviet Union’ (Former Soviet Union (FSU) countries: Armenia, Azerbaijan, Belarus, Estonia (EU), Georgia, Kazakhstan, Kyrgyzstan, Latvia (EU), Lithuania (EU), Moldova, Russian Federation, Tajikistan, Turkmenistan, Ukraine and Uzbekistan) or ‘Yugoslavia’ (Bosnia and Herzegovina, Croatia (EU), Kosovo*, Montenegro, Serbia, Slovenia (EU) and the former Yugoslav Republic of Macedonia) were classified as cases of unspecified origin (n = 114), because some parts of those two historical countries belong to the EU today as indicated in brackets.

Liechtenstein reported TB surveillance data to TESSy only for 2007 and was therefore excluded from the analysis. Croatia joined the EU in July 2013 and was considered a non-EU/EEA country in the analysis. France, Italy, and Spain are not reporting drug resistance data to TESSy and were excluded from the analysis of laboratory data and drug resistance. Treatment outcome data were not reported by France, Greece, and Italy in...
2007–2012, and by Spain in 2007–2009. Therefore, these countries were excluded from the treatment outcome analysis. TB treatment was considered successful if a case was cured or their treatment completed 12 months after start of treatment.

TB cases were described by year of reporting, origin and country of reporting. Native cases (EU/EEA origin) and cases from outside the EU/EEA were compared by sex, age, previous treatment history, TB site, laboratory confirmation status, drug resistance, HIV status and treatment outcome. Differences were considered statistically significant, if $p<0.01$ as determined by
Figure 4: Distribution of tuberculosis cases originating from India, Pakistan, Somalia, Morocco, Turkey, Russian Federation, Bangladesh and the Philippines across the five European Union/European Economic Area countries with the highest reported numbers, 2007–2013 (n=47,440)

EEA: European Economic Area; EU: European Union; TB: tuberculosis.
<table>
<thead>
<tr>
<th>WHO Region</th>
<th>Total</th>
<th>EU/EEA Total</th>
<th>Eastern Mediterranean</th>
<th>South-East Asian</th>
<th>African</th>
<th>European (excluding EU/EEA)</th>
<th>Western Pacific</th>
<th>Americas</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>%</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Total</td>
<td>491,538</td>
<td>81.3</td>
<td>91,925</td>
<td>18.7</td>
<td>26,945</td>
<td>29.3</td>
<td>21,097</td>
<td>23.0</td>
</tr>
</tbody>
</table>

**Sex**

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>66.1</td>
<td>33.8</td>
<td>0.1</td>
</tr>
<tr>
<td>N</td>
<td>264,686</td>
<td>335,220</td>
<td>325</td>
</tr>
</tbody>
</table>

**Age groups (years)**

<table>
<thead>
<tr>
<th></th>
<th>0–14</th>
<th>15–24</th>
<th>25–44</th>
<th>45–64</th>
<th>65+</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>4.5</td>
<td>9.8</td>
<td>30.7</td>
<td>33.8</td>
<td>21.0</td>
<td>0.1</td>
</tr>
<tr>
<td>N</td>
<td>18,034</td>
<td>39,266</td>
<td>122,780</td>
<td>135,147</td>
<td>83,946</td>
<td>440</td>
</tr>
</tbody>
</table>

**Previous TB history**

<table>
<thead>
<tr>
<th></th>
<th>No</th>
<th>Yes</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>79.4</td>
<td>20.6</td>
<td>0.1</td>
</tr>
<tr>
<td>N</td>
<td>317,268</td>
<td>58,781</td>
<td>23,564</td>
</tr>
</tbody>
</table>

**Site of disease**

<table>
<thead>
<tr>
<th></th>
<th>Pulmonary</th>
<th>Extra-pulmonary</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>83.6</td>
<td>16.3</td>
<td>0.2</td>
</tr>
<tr>
<td>N</td>
<td>333,989</td>
<td>64,968</td>
<td>656</td>
</tr>
</tbody>
</table>

**Drug resistance among DST done**

<table>
<thead>
<tr>
<th></th>
<th>DST done among laboratory confirmed</th>
<th>Susceptible</th>
<th>Mono-resistant</th>
<th>Poly-resistant</th>
<th>MDR among DST done</th>
<th>XDR among MDR</th>
<th>HIV status</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>68.5</td>
<td>86.3</td>
<td>6.9</td>
<td>2.0</td>
<td>1.9</td>
<td>0.8</td>
<td>Tested for HIV</td>
</tr>
<tr>
<td>N</td>
<td>147,090</td>
<td>126,945</td>
<td>8,664</td>
<td>8,281</td>
<td>8,660</td>
<td>691</td>
<td>83,062</td>
</tr>
</tbody>
</table>

**Laboratory data not reported**

<table>
<thead>
<tr>
<th></th>
<th>20.8</th>
<th>6.4</th>
<th>6.0</th>
<th>3.0</th>
<th>9.6</th>
<th>5.9</th>
<th>0.8</th>
<th>8.0</th>
<th>5.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>26,945</td>
<td>12,097</td>
<td>813</td>
<td>270</td>
<td>199</td>
<td>6</td>
<td>32</td>
<td>18</td>
<td>32</td>
</tr>
</tbody>
</table>

DST: drug susceptibility testing; MDR: multidrug resistant; EEA: European Economic Area; EU: European Union; N: number; WHO: World Health Organization; XDR: extensively drug resistant.

* Percentage among TB cases in individuals of non-EU/EEA origin.
chi-squared test. Statistical analysis was performed using Stata 13 software (StataCorp, Texas, US).

Results

Of 527,467 TB cases notified in the EU/EEA from 2007 to 2013, 399,613 (75.8%) were reported as originating from EU/EEA countries, 92,039 (17.4%) as originating from non-EU/EEA countries, and for 35,815 (6.8%), country of origin was not reported. Among 491,652 TB cases with reported country of origin, 122,627 (24.9%) originated from outside the reporting country. Of these, 91,925 (75%) originated from outside the EU/EEA, 30,588 (24.9%) were of EU/EEA origin, and 114 (0.1%) originated from ‘Soviet Union’ or ‘Yugoslavia’. The proportion of TB cases with reported non-EU/EEA origin increased from 13.6% (n = 14,050) in 2007 to 21.8% (n = 14,050) in 2013, the proportion of TB cases with reported EU/EEA origin decreased from 77.8% (n = 65,390) in 2007 to 73.4% (n = 47,185) in 2013, while the proportion of TB cases with unknown or unspecified origin decreased from 8.6% (n = 7,221) to 4.8% (n = 3,092) in the same period (p < 0.001) (Figure 1).

Of 92,039 cases with non-EU/EEA origin, the country of origin was reported for 91,925 (99.9%) cases, with the majority coming from the Eastern Mediterranean Region (29.3%, n = 26,945), the South-East Asian Region (23.0%, n = 21,097) and the African Region (21.4%, n = 19,629) (Table).

Compared with native TB cases, TB cases in individuals of non-EU/EEA origin were more frequently female (42.0% vs 33.8%, p < 0.001) and under 45 years of age (71.8% vs 45.1%, p < 0.001) (Table). Cases of non-EU/EEA origin had a previous TB history less frequently (6.2% vs 14.7%, p < 0.001), but a proportion of cases with unknown previous history three times higher than native cases. Extrapulmonary TB was much more commonly diagnosed in cases of non-EU/EEA origin (41.8% vs 16.3%, p < 0.001). Very similar proportions, just over 50% of cases were laboratory-confirmed in both native and migrant cases, but the latter were much more extensively tested for drug susceptibility (97.0% vs 68.5%, p < 0.001), and were found to be mono-resistant and poly-resistant slightly more frequently, but not multidrug-resistant (9.9% vs 2.9%, p < 0.001). The majority of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB cases in individuals of non-EU/EEA origin were from the European Region, where the highest percentage of MDR-TB cases among the cases with available drug susceptibility testing (DST) results (9.6%, n = 704) was observed, as well as the highest percentage of XDR-TB cases among MDR-TB (9.7%, n = 68). Of 704 MDR-TB cases originating from the European Region, 678 (96.3%) were notified in cases coming from 13 non-EU/EEA ‘Soviet Union’ countries (data not shown). The highest percentage of mono-resistance to a first-line anti-TB drug was observed in cases originating from the Western Pacific Region (10.4%, n = 358). Most cases with mono-resistance originated from the Philippines, Vietnam and China (145, 117 and 48 respectively). Among the mono-resistant TB cases from the Philippines, Vietnam and China, 83.4% (n = 121) were resistant to isoniazid, while in cases originating from Vietnam and China, 55.6% (n = 65) and 60.4% (n = 29) were resistant to isoniazid (data not shown). In the period 2007–2013 the trend in MDR-TB prevalence among cases of non-EU/EEA origin did not significantly change (Figure 1).
not change significantly \((p=0.94,\) data not shown)\). Cases of non-EU/EEA origin were tested for HIV much less frequently than native cases \((6.4\% \text{ vs } 20.8\%, p<0.001)\), but tested HIV-positive twice as often \((9.6\% \text{ vs } 4.8\%, p<0.001)\). Among cases of non-EU/EEA origin, the majority and highest prevalence of HIV co-infection was found in cases originating from the African Region. A higher proportion of treatment success was reported in migrant cases \((77.4\% \text{ vs } 74.6\%, p<0.001)\), while the proportion that died during treatment was lower \((3.2\% \text{ vs } 8.2\%, p<0.001)\). The percentage of TB cases where the treatment outcome was ‘lost to follow-up’ was lower in the cases of non-EU/EEA origin \((5.4\% \text{ vs } 6.6\%))\, but the percentage of non-evaluated cases was higher \((7.0\% \text{ vs } 5.2\%)\). The lowest treatment success rate, 70.4\%, was observed among cases from the European Region.

From 2007 to 2011, the number of notified TB cases in individuals of non-EU/EEA origin increased for all WHO Regions except for the European region (Figure 2). Thereafter, the number remained the same or decreased slightly. In the same period, the number of TB cases with unknown country of origin decreased from 8.6% in 2007 to 4.8% in 2013. The mean annual increase in the period 2007–2011 was highest for cases originating from Americas \((13.5\%\); standard deviation \((SD): 18.4)\), followed by the African Region \((10.9\%\); SD: 20.4), the South-East Asian Region \((8.9\%\); SD: 8.1), the Eastern Mediterranean Region \((8.9\%\); SD: 5.3) and the Western Pacific Region \((2.8\%\); SD: 4.2), while for cases originating from the European Region a mean annual decrease of 1.3% \((SD: 3.7))\ was observed. The mean increase in the number of notified cases was the highest for cases originating from the Eastern Mediterranean Region \((n = 309; SD: 183.1))\, followed by the African Region \((n = 256; SD: 411.3))\, the South-East Asian Region \((n = 248; SD: 238.2))\, the Americas \((n = 75; SD: 145.1))\ and the Western Pacific Region \((n = 25; SD: 52.7))\. The notification of cases originating from the European Region showed the mean decrease of 26 cases annually \((SD: 63.2))\.

Of all TB cases in individuals of non-EU/EEA origin, 40.9% \((n = 37,573)\) were reported by the United Kingdom \((UK)\), 12.8% \((n = 11,728)\) by Germany and 10.3% \((n = 9,264)\) by Italy (Figure 3A). The highest contribution of TB cases in individuals of non-EU/EEA origin to the national TB burden was observed in Norway with 82.4% \((n = 1,997)\), Sweden with 79.9% \((n = 3,274)\) and Malta with 78.1% \((n = 228)\) (Figure 3B).

The reported non-EU/EEA TB cases originated from 186 countries, dependent territories, and special areas of geographical interest with 51.6% coming from India \((15.3\%))\, Pakistan \((10.9\%))\, Somalia \((8.5\%))\, Morocco \((5.7\%))\, Turkey \((3.0\%))\, Russian Federation \((2.9\%))\, Bangladesh \((2.7\%))\, and the Philippines \((2.6\%))\). Their distribution mirrors the typical migration flows and destination country preferences (Figure 4). Between 2007 and 2013, increasing numbers of TB cases from India, Pakistan and Morocco were notified \((p<0.001,\) data not shown)\.

Most cases from India \((80.3\%, n = 11,293)\) were reported by the UK (Figure 4). The UK also reported a large percentage of the cases originating from Pakistan \((70.5\%, n = 7,073))\, from Somalia \((41.2\%, n = 3,228))\, from Bangladesh \((74.7\%, n = 1,833))\, and from Philippines \((36.7\%, n = 892))\. Germany reported 66.8% \((n = 1,818)\) of all reported cases from Turkey and 40.6% \((n = 1,091)\) of all reported cases from Russian Federation. While, Italy reported the largest percentage of cases from Morocco \((28.7\%, n = 1,493))\.

**Discussion**

Almost one in five TB cases notified in the EU/EEA between 2007 and 2013 originated from a country outside the EU/EEA, but this varied from \(<1\% \text{ to } >80\%\) between the 29 countries included in this study. The percentage of migrant TB cases increased from 13.6% to 21.8% between 2007 and 2013, while the overall number of cases of non-EU/EEA origin increased from 11,403 in 2007 to 14,975 in 2011 and slightly decreased thereafter to 14,050 in 2013. The increasing percentage of migrant TB among all notified TB cases is largely attributable to the decreasing numbers of native TB cases and cases with unknown origin. The highest mean annual increase in notifications was observed in TB cases originating from the Eastern Mediterranean and African Regions. The only decreasing trend was seen in cases originating from the European Region. Increasing trends in notified TB cases in migrants have also been observed in other high-income countries such as Australia, Canada, and the United States (US) [17-19].

TB cases originating from eight countries accounted for 51.6% of all TB cases in individuals of non-EU/EEA origin. This can be explained by the burden of TB in these countries [15] and the relatively high number of migrants from these countries to the EU/EEA [5,6]. Data from Australia, Canada and the US showed that the TB notification rate among migrants is strongly associated with the TB burden in the country of origin [18]. Among foreign-born and US-born cases in the US, the level of education, living conditions, low income and unemployment were associated with higher TB rates; this association was stronger in the foreign-born cases. According to the authors, these results support the hypothesis that the TB rates among foreign-born cases are more strongly influenced by experiences in their country of origin than by the environments in the host country [19]. Similarly to the situation in the EU/EEA, the 25 to 44 years-old age group was most represented in the US among foreign-born TB cases [20]. In the EU/EEA, the high proportions of males seen among cases originating from the Eastern Mediterranean and European Regions suggest that the majority of TB cases from these regions are migrant workers. This is supported by Eurostat data according to which, on average
29% of residence permits were issued in 2008–2012 due to employment and 28% due to family reasons [5].

Exposure to TB before immigration to the EU/EEA and when travelling back to the country of origin for family visits may result in relatively high latent TB infection rates in migrant populations [21–23]. Several studies suggest that the majority of cases among migrants occur due to TB infection or reinfecion when travelling to their home country [20,24,25] or due to reactivation of latent TB [20,26,27]. However, TB in migrants might also be due to recent infection or reinfecion in the host country after local exposure [27–30].

According to the Eurostat data, there are remarkable differences in the number of migrants received by different EU/EEA countries. The UK, Italy, Germany, France, the Netherlands and Spain received the highest number of non-EU/EEA migrants during the period 2007–2012 [4]. In most EU/EEA Member States, this migration peaked in 2010, which was probably largely attributable to the global financial crisis [4,31]. Both the geographical distribution of reported TB cases in individuals of non-EU/EEA origin and their overall trend over time appears to follow the general migration patterns described [5,20]. As the biggest reporting country of TB cases in individuals of non-EU/EEA origin, the UK saw the majority of these cases originating from India, Pakistan and Bangladesh. The same three countries were also among the top five countries contributing to the TB burden in the US [20].

The highest prevalence of MDR-TB and XDR-TB was observed among cases of non-EU/EEA European origin. In the US in 2007–2009, 1.5% of foreign-born cases with available DST results were reported with MDR-TB, and the highest percentage (9.3%) was also observed among cases of European origin [32]. Equally, in Canada, the highest percentage of MDR-TB cases (2.9%) among foreign-born TB cases originated from the European Region [33]. This reflects the high prevalence of drug resistance among TB cases in the non-EU/EEA European Region [15].

Extrapulmonary TB was more frequently reported in TB cases in individuals of non-EU/EEA origin. Since extrapulmonary TB (excluding laryngeal TB) is rarely infectious, these cases will not contribute to transmission in the host country but do have an impact on health service costs. Further, extrapulmonary TB can result in significant suffering [34] and the diagnosis is often challenging [35]. Therefore, healthcare workers need to have a relatively high level of suspicion when persons of non-EU/EEA origin present with unexplained signs and symptoms that might be caused by extrapulmonary TB.

As expected, given the global HIV situation [36], most HIV co-infections were observed among cases of African and Western Pacific origin.

In Japan, 63.4% foreign-born smear-positive TB cases had a successful treatment outcome in the period 2007–2010 [37]. The situation in the EU/EEA is much better with 77.4% of TB cases in individuals of non-EU/EEA origin having a successful treatment outcome 12 months after starting treatment. Among TB cases in individuals of non-EU/EEA origin notified in EU/EEA, 17.9% percent did not have treatment outcome data reported, while in Japan, treatment outcome was not available for 16.6% of foreign-born smear-positive cases [37]. In the EU/EEA, the lowest treatment success rate (70.4%) was observed in cases from the European Region. This is probably attributable to the high percentage of MDR TB and XDR TB cases which require more than 12 months of treatment and would therefore be reported as ‘still on treatment’ 12 months after starting treatment. Another reason may be the high percentage of non-evaluated cases (10.0%) which might mask the real number of cases lost to follow-up. The non-uniform use of treatment outcome categories such as ‘lost to follow-up’, ‘transferred out’, ‘still on treatment’ and ‘unknown’ across the EU/EEA Member States might contribute to the high number of cases with non-evaluated treatment outcome [38]. In contrast to an earlier publication from the year 2000 that covers the period 1993-1997, where origin from ‘Eastern Europe’ and ‘Yugoslavia’ were identified as risk factors for loss to follow-up [39], the percentage of this treatment outcome in our study was smaller in TB cases in individuals of non-EU/EEA origin than in cases of EU/EEA origin. The percentage was especially low in cases originating from the European Region outside the EU/EEA. The treatment success rate in TB cases in individuals of non-EU/EEA origin was higher compared with native TB cases (77.4% vs 74.6%), and the fatality rate was lower (3.2% vs 8.2%). The percentage of TB cases over 64 years of age was lower in migrants compared with native TB cases (8.9% vs 21.0%) which explains the treatment outcome results.

Limitations
This study is based on TB surveillance data submitted to ECDC by the EU/EEA countries. In the EU/EEA TB surveillance system, only a limited number of variables are collected. Also, not all reported information is complete, and data quality is primarily the responsibility of the individual country. The origin of 6.8% of TB cases notified between 2007 and 2013 was not reported. In addition, three countries did not report case-based drug resistance data, and four countries did not report case-based treatment outcome data for the whole period. Due to this missing information, our results might not provide the complete picture of TB epidemiology among cases of non-EU/EEA origin. Furthermore, TB rates among immigrants could not be calculated due to the unavailability of migrant population data.

The differences in reporting of country of origin (country of birth vs nationality) might affect the comparability of data between some countries. The burden of non-EU/EEA migrant TB cases might be underestimated.
in countries reporting nationality, as the migrants might have obtained the citizenship of the host country before TB was diagnosed. Italy, France and Spain are not reporting TB drug resistance data to TESSy. The exclusion of TB cases reported by these countries compromises the representativeness of laboratory results in this study as these three countries received a relatively high number of non-EU/EEA immigrants.

The laboratory confirmation rate has been shown to be below 50% in some major reporting countries EU/EEA MSs [1] which might lead to the underestimation of resistant TB cases.

The HIV testing coverage among TB cases is suboptimal and does therefore not allow for an in-depth analysis of the data. The low testing coverage might lead to under- or over estimation of TB/HIV co-infection in EU/EEA.

Conclusions
Migration from outside the EU/EEA contributes markedly to the TB burden in the EU/EEA. Targeted prevention and control efforts (e.g. access to healthcare for all migrants including undocumented migrants, avoiding interruption of treatment) and implementation of active case finding approaches (e.g. screening at entry point, screening for latent TB infection) focussed on non-EU/EEA migrants may be needed in order to diagnose cases early, provide adequate treatment and support and reduce the burden of TB among migrants.

*This designation is without prejudice to positions on status, and is in line with United Nations Security Council resolution 1244/99 and the International Court of Justice Opinion on the Kosovo declaration of independence.

Acknowledgements
The authors acknowledge the nominated national operational contact points for tuberculosis (in alphabetical order): Peter Henrik Andersen, Delphine Antoine, Trude Margrete Gjøen Andrea, Walter Haas, Alexander Indra, Jerker Jonsson, Ourania Kalkouni, Maria Koliou, Maria Korzeniewska – Kosela, Gábor Kovács, Joan O’Donnell, Analita Pace Asciak, Maria Pascual, Elena Rodrigues Valín, Alexandar Simunovic, Erika Slump, Hanna Soini, Ivan Solovič, Petra Svenska, Lucy Thomas, Tonka Varleva, Piret Viiklepp, Kate Vulāne, Jiří Wallenfels and Maryse Wanlin, who provided the surveillance data used in this analysis.

No specific sources of funding were used for this study. The authors performed the study as part of their job at ECDC.

Conflict of interest
None declared.

Authors’ contributions
CK contributed to the study design, performed the data analysis, and wrote the first draft of the manuscript. PZ contributed to the study design, and contributed to further versions of the manuscript and approved the final version before submission. MvdW contributed to the study design and data analysis, and contributed to further versions of the manuscript and approved the final version before submission.

References


License and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors, 2016.